BioCentury | Apr 17, 2021
Deals

As German translational science begins to bloom, Evotec, BMS launch incubator in Rhine-Main-Neckar region

An improving environment for translational science in Germany has prompted Evotec to launch its latest incubator in the country. This week Evotec SE (Xetra:EVT) announced that it has partnered with Bristol Myers Squibb Co. (NYSE:BMY)...
BioCentury | Apr 17, 2021
Finance

Biotech IPOs continue attracting cash

A trio of IPOs on Friday continued the trend of strong debuts by biotech companies on NASDAQ. The offerings from Recursion, Biomea and Akoya all priced at the top of their range and traded up in the...
BioCentury | Apr 15, 2021
Emerging Company Profile

How SV-seeded Alchemab is searching for mAbs in super responders

Alchemab is mining the B cell repertoires of super responders, a strategy used for discovering potent mAbs to treat infectious diseases, and applying the same principle to difficult-to-treat cancer and...
BioCentury | Apr 15, 2021
Finance

Slumping shares and setbacks make GSK a target for activist investors

Although GSK has declined to comment on reports that Elliott Management has built up a “substantial” position in the British pharma, a string of setbacks has deflated GSK’s valuation enough in the past year to...
BioCentury | Apr 14, 2021
Finance

Tango & Cash: the latest in string of biotech SPAC mergers: Data Byte

Tango and Surrozen completed SPAC deals this week to bring the total number of biotech SPAC mergers to at least 22. Tango Therapeutics Inc., a synthetic lethality company, said on Wednesday it is merging with BCTG Acquisition...
BioCentury | Apr 13, 2021
Regulation

Competence & continuity at CDER; plus BIO 3.0, AACR and 2Q preview: a BioCentury podcast

On the latest BioCentury This Week podcast, BioCentury editors discuss what Patrizia Cavazzoni’s appointment as permanent director of FDA’s Center for Drug Evaluation and Research means for the biopharma...
BioCentury | Apr 10, 2021
Finance

2Q21 Preview: Looking for signals of financing slowdown

The first quarter of 2021 saw a disconnect emerge between market performance and financing activity. While biotech financings set first quarter records across IPOs, follow-ons and venture, sector indexes...
BioCentury | Apr 8, 2021
Emerging Company Profile

Crossovers Fidelity, Surveyor invest early in ValenzaBio, backing $70M series A for rare autoimmune play

With a $70 million series A round led by Fidelity in a syndicate that included crossover Surveyor, start-up ValenzaBio is readying to take antibodies licensed from CRUK and Pierre Fabre into early clinical...
BioCentury | Mar 26, 2021
Politics, Policy & Law

Abernethy tackled ‘the blooming obvious’ at FDA by improving tech and data

When Amy Abernethy joined FDA as principal deputy commissioner, “there were two things that were just blooming obvious,” she told BioCentury as she prepared to wind up a two-year stint at the agency....
BioCentury | Mar 25, 2021
Management Tracks

Slaoui stepping back from all biopharma roles, expresses ‘deep regrets’ following sexual harassment claim

Former Operation Warp Speed leader Moncef Slaoui implied that he is taking a leave of absence from all his professional roles following his termination as Galvani’s chairman by GSK due to sexual harassment allegations. Slaoui, a 30-year...
Items per page:
1 - 10 of 3111
BioCentury | Apr 17, 2021
Deals

As German translational science begins to bloom, Evotec, BMS launch incubator in Rhine-Main-Neckar region

An improving environment for translational science in Germany has prompted Evotec to launch its latest incubator in the country. This week Evotec SE (Xetra:EVT) announced that it has partnered with Bristol Myers Squibb Co. (NYSE:BMY)...
BioCentury | Apr 17, 2021
Finance

Biotech IPOs continue attracting cash

A trio of IPOs on Friday continued the trend of strong debuts by biotech companies on NASDAQ. The offerings from Recursion, Biomea and Akoya all priced at the top of their range and traded up in the...
BioCentury | Apr 15, 2021
Emerging Company Profile

How SV-seeded Alchemab is searching for mAbs in super responders

Alchemab is mining the B cell repertoires of super responders, a strategy used for discovering potent mAbs to treat infectious diseases, and applying the same principle to difficult-to-treat cancer and...
BioCentury | Apr 15, 2021
Finance

Slumping shares and setbacks make GSK a target for activist investors

Although GSK has declined to comment on reports that Elliott Management has built up a “substantial” position in the British pharma, a string of setbacks has deflated GSK’s valuation enough in the past year to...
BioCentury | Apr 14, 2021
Finance

Tango & Cash: the latest in string of biotech SPAC mergers: Data Byte

Tango and Surrozen completed SPAC deals this week to bring the total number of biotech SPAC mergers to at least 22. Tango Therapeutics Inc., a synthetic lethality company, said on Wednesday it is merging with BCTG Acquisition...
BioCentury | Apr 13, 2021
Regulation

Competence & continuity at CDER; plus BIO 3.0, AACR and 2Q preview: a BioCentury podcast

On the latest BioCentury This Week podcast, BioCentury editors discuss what Patrizia Cavazzoni’s appointment as permanent director of FDA’s Center for Drug Evaluation and Research means for the biopharma...
BioCentury | Apr 10, 2021
Finance

2Q21 Preview: Looking for signals of financing slowdown

The first quarter of 2021 saw a disconnect emerge between market performance and financing activity. While biotech financings set first quarter records across IPOs, follow-ons and venture, sector indexes...
BioCentury | Apr 8, 2021
Emerging Company Profile

Crossovers Fidelity, Surveyor invest early in ValenzaBio, backing $70M series A for rare autoimmune play

With a $70 million series A round led by Fidelity in a syndicate that included crossover Surveyor, start-up ValenzaBio is readying to take antibodies licensed from CRUK and Pierre Fabre into early clinical...
BioCentury | Mar 26, 2021
Politics, Policy & Law

Abernethy tackled ‘the blooming obvious’ at FDA by improving tech and data

When Amy Abernethy joined FDA as principal deputy commissioner, “there were two things that were just blooming obvious,” she told BioCentury as she prepared to wind up a two-year stint at the agency....
BioCentury | Mar 25, 2021
Management Tracks

Slaoui stepping back from all biopharma roles, expresses ‘deep regrets’ following sexual harassment claim

Former Operation Warp Speed leader Moncef Slaoui implied that he is taking a leave of absence from all his professional roles following his termination as Galvani’s chairman by GSK due to sexual harassment allegations. Slaoui, a 30-year...
Items per page:
1 - 10 of 3111